RenovoRx (RNXT) Cash from Financing Activities (2020 - 2026)
RenovoRx (RNXT) posted Cash from Financing Activities of $9.0 million for Q1 2026, up 26508.82% sequentially from $34000.0 in Q2 2025, and down 16.32% YoY from $10.8 million in Q1 2025.
RenovoRx (RNXT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
RenovoRx has reported Cash from Financing Activities for 7 years, with the latest figure at $9.0 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 16.32% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 55.72% YoY) and the FY2025 annual result came in at $10.8 million, down 28.26% from the prior year.
- Cash from Financing Activities advanced to $9.0 million in Q1 2026 per RNXT's latest filing, from $34000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.8 million in Q1 2025 and troughed at $3000.0 in Q4 2022.
- A 5-year average of $3.1 million and a median of $33000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 99.98% in 2022, then soared 90233.33% in 2024.
- Over 5 years, Cash from Financing Activities stood at $3000.0 in 2022, then surged by 166633.33% to $5.0 million in 2023, then tumbled by 99.34% to $33000.0 in 2024, then gained by 3.03% to $34000.0 in 2025, then jumped by 26508.82% to $9.0 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $9.0 million, $34000.0, and $10.8 million for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | 55,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55,000.00 |
| Jun 30, 2026 | 55,000.00 |
| Mar 31, 2026 | 9.05 Mn |
| Mar 31, 2026 | 9.05 Mn |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 10.81 Mn |
| Mar 31, 2025 | 10.81 Mn |
| Dec 31, 2024 | 33,000.00 |
| Dec 31, 2024 | 33,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 9.65 Mn |
| Jun 30, 2024 | 9.65 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Jun 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 5.00 Mn |
| Mar 31, 2023 | 6,000.00 |
| Mar 31, 2023 | 6,000.00 |